PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18670083-7 2008 SDS significantly protected APAP-induced hepatotoxicity for SDS improved mouse survival rates better than NAC against a lethal dose of APAP and significantly blocked not only APAP-induced increases of AST, ALT, and TNF-alpha but also APAP-induced GSH depletion and MDA accumulation. rhodioloside 0-3 tumor necrosis factor Mus musculus 215-224 35583558-6 2022 SAL treatment alleviated Cd-induced oxidative stress, glial cell activation, and elevation of pro-inflammatory factors including TNF-alpha, IL-1beta, and IL-6. rhodioloside 0-3 tumor necrosis factor Mus musculus 129-138 34988203-9 2021 Sal reduced the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-8. rhodioloside 0-3 tumor necrosis factor Mus musculus 26-53 34988203-9 2021 Sal reduced the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-8. rhodioloside 0-3 tumor necrosis factor Mus musculus 55-64 35561751-7 2022 Further, the increased levels of TNF-alpha, IL-1beta and IL-6 were confined with Sal administration under the HH condition. rhodioloside 81-84 tumor necrosis factor Mus musculus 33-42 35189918-12 2022 The SAL coating had anti-inflammatory activity by reducing the levels of TNF-alpha and IL-6 in vivo. rhodioloside 4-7 tumor necrosis factor Mus musculus 73-82 30836660-10 2019 Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha). rhodioloside 14-17 tumor necrosis factor Mus musculus 209-218 31792327-9 2019 SAL down-regulated the expression levels of TNF-alpha, TGF-beta1, IL-1beta, Bax and up-regulate the expression of Bcl-2, VEGF, Akt and eNOS. rhodioloside 0-3 tumor necrosis factor Mus musculus 44-53 31849652-7 2019 Simultaneously, Sal alleviated excessive inflammation by reversing the IL-1beta, TNF-alpha, and IL-10 protein levels in DSS-treated mice. rhodioloside 16-19 tumor necrosis factor Mus musculus 81-90 29926065-9 2018 The result showed that salidroside pretreatment decreased the expression of IL-6 and TNF-alpha as well as phosphorylation of p38 and JNK induced by LPS in BV-2 cells. rhodioloside 23-34 tumor necrosis factor Mus musculus 85-94 30654097-3 2019 SAL significantly modified the intestinal microbial diversity and downregulated the circulating levels of serum LPS, IL-6, and TNF-alpha, as well as enhanced the content of IL-10. rhodioloside 0-3 tumor necrosis factor Mus musculus 127-136 27928219-7 2016 The SDS reduced the inflammatory cells in BALF, decreased the wet/dry ratio of lungs, attenuated the LPS-induced histological alterations in the lung, and inhibited the production of TNF-alpha, IL-1beta, and IL-6. rhodioloside 4-7 tumor necrosis factor Mus musculus 183-192 28931916-8 2017 Salidroside significantly decreased the serum TNF-alpha, IL-6, NO, and HMGB1 productions, pulmonary inducible NO synthase (iNOS) and phosphorylated NF-kappaB-p65 protein expressions, and pulmonary HMGB1 nuclear translocation in CLP septic mice. rhodioloside 0-11 tumor necrosis factor Mus musculus 46-55 27978494-6 2017 Sal also inhibited the generations of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in serum and lungs. rhodioloside 0-3 tumor necrosis factor Mus musculus 75-102 27978494-6 2017 Sal also inhibited the generations of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in serum and lungs. rhodioloside 0-3 tumor necrosis factor Mus musculus 104-113 29693192-5 2018 In our study, we found that SR dose-dependently ameliorated skin cancer incidence and the multiplicity in the animal models by reducing the release of inflammation-related cytokines, including tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-18 (IL-18), interleukin-6 (IL-6), cyclooxygenase 2 (COX2) and transforming growth factor beta-1 (TGF-beta1). rhodioloside 28-30 tumor necrosis factor Mus musculus 193-220 29693192-5 2018 In our study, we found that SR dose-dependently ameliorated skin cancer incidence and the multiplicity in the animal models by reducing the release of inflammation-related cytokines, including tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-18 (IL-18), interleukin-6 (IL-6), cyclooxygenase 2 (COX2) and transforming growth factor beta-1 (TGF-beta1). rhodioloside 28-30 tumor necrosis factor Mus musculus 222-231 29568861-11 2018 In addition, it was demonstrated that salidroside administration suppressed the expression levels of IL-6 and TNF-alpha. rhodioloside 38-49 tumor necrosis factor Mus musculus 110-119 29568861-13 2018 Furthermore, it was demonstrated that the effects of salidroside administration on AD mice were, at least partially, via inhibition of brain oxidative/nitrosative damage, suppression of both IL-6 and TNF-alpha expression levels, and suppression of the hippocampal neuronal apoptotic rate. rhodioloside 53-64 tumor necrosis factor Mus musculus 200-209 27834881-6 2016 SDS significantly inhibited protein secretion and mRNA expression of of interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha. rhodioloside 0-3 tumor necrosis factor Mus musculus 99-132 22915087-5 2013 Salidroside administered 1 h before LPS infusion significantly attenuated inflammatory cell infiltration, reduced the activity of myeloperoxidase in mammary tissue, and decreased the concentration of tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 in a dose-dependent manner. rhodioloside 0-11 tumor necrosis factor Mus musculus 200-227 22776035-4 2012 In addition, salidroside also inhibited the production of several inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-6 (IL-6) and IL-1beta, and the NF-kappaB DNA-binding activation after LPS challenge. rhodioloside 13-24 tumor necrosis factor Mus musculus 100-127 22019446-4 2011 Salidroside significantly attenuated TNF-alpha, IL-1beta and IL-6 productions in serum from mice challenged with LPS, and consistent with the results in vitro. rhodioloside 0-11 tumor necrosis factor Mus musculus 37-46